RALEIGH, N.C., Jan. 6, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) today announced the signing of a worldwide license and development agreement with Endo Pharmaceuticals (Nasdaq: ENDP) for the exclusive rights to develop and commercialize BEMA Buprenorphine for the treatment of chronic pain. BEMA Buprenorphine utilizes BDSI's ... read more

RALEIGH, N.C., Dec. 29, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) responded to the approval and announcement by the U.S. Food and Drug Administration (FDA) that a Risk Evaluation Mitigation Strategy (REMS) covering all transmucosal fentanyl products has been approved. The program, which ... read more

RALEIGH, N.C., Dec. 20, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced results from its confirmatory study, BNX-102, assessing the pharmacokinetics of its BEMA Buprenorphine/Naloxone (BNX) formulation compared to Suboxone. The results confirm the final formulation and provide the basis for moving forward ... read more

RALEIGH, N.C., Nov. 28, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) has been informed by the United States Patent & Trademark Office (USPTO) that it has rejected all claims of US Patent No. 7,824,588 (the '588 Patent) which is currently being asserted against BDSI ... read more

RALEIGH, N.C., Nov. 21, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the 23rd Annual Piper Jaffray Healthcare Conference at The New York Palace, New York City. The presentation ... read more

RALEIGH, N.C., Nov. 14, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) will host a webcast and conference call on Tuesday, November 15, 2011 at 8:30 AM Eastern Time to provide a business update which will include plans and timelines for BEMA Buprenorphine/Naloxone for the treatment of opioid dependence ... read more

RALEIGH, N.C., Nov. 10, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that it has initiated a confirmatory pharmacokinetic study of a formulation of buprenorphine and naloxone utilizing BDSI's patented BioErodible MucoAdhesive (BEMA) drug delivery technology. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) The study, BNX-102, will be used to select the final ... read more

RALEIGH, N.C., Nov. 7, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that TTY Biopharm Co., Ltd. (TTY), BDSI's commercial partner for BEMA Fentanyl in Taiwan, has submitted a New Drug Application (NDA) for marketing authorization of BEMA Fentanyl to the Taiwan Food and Drug Administration. (Logo: ... read more

RALEIGH, N.C., Oct. 25, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Samuel P. Sears, Jr. has been appointed as an independent director of the Company effective October 21, 2011. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) Mr. Sears has extensive experience in the biopharmaceutical, nutraceutical and biotechnology industries. Since 2006, Mr. ... read more

RALEIGH, N.C., Sept. 28, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced the preliminary findings of the Company's randomized, placebo-controlled, Phase 3 clinical study of BEMA Buprenorphine for the treatment of moderate to severe chronic pain in a mixed opioid naive and opioid experienced population. The primary ... read more

RALEIGH, N.C., Sept. 6, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced positive preliminary results from its Phase 1 study assessing the pharmacokinetics of a BEMA Buprenorphine/Naloxone formulation. BDSI is seeking to develop and commercialize a high dose formulation of buprenorphine combined with naloxone (abuse deterrent agent) ... read more

RALEIGH, N.C., Aug. 31, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) today announced its participation at three upcoming investor conferences. Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at each conference where he will focus on BDSI's product pipeline, particularly BEMA Buprenorphine for the ... read more

RALEIGH, N.C., Aug. 22, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) today announced that the commercial launch and availability of ONSOLIS (fentanyl buccal soluble film) in Canada will take place this quarter. (LOGO: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) ONSOLIS is approved in the U.S., Canada, and the E.U. (where it will ... read more